The Therapeutic Goods Administration has recently made a number of updates to the database of medicine shortages and newly approved replacements
Among the new listings or updates are:
Fluoxetine capsules USP 20mg (ScieGen) 100 capsule bottle have been added as an approved product (till 30 April 2021) due to shortages of Prozac 20 fluoxetine 20mg (as hydrochloride) capsule and Lovan fluoxetine 20mg (as hydrochloride) capsule.
These medicines have been impacted by manufacturing issues, with shortages expected to continue till March 2021 (for Lovan) and the end of 2020 (for Prozac).
A number of fluoextine products have been impacted by ongoing shortages or have been discontinued. See here for a full listing of these products.
The newly listed product is being distributed by Medsurge Healthcare (Ph: 1300 788 261).
Teva-Prazosin (Prazosin hydrochloride) 5mg, 2mg and 1mg tablets have been approved until 15 February 2021.
These products are to substitute for Minipress prazosin 5 mg, 2mg and 1mg (as hydrochloride) tablet blister packs and for Apo-Prazosin prazosin (as hydrochloride) 2mg tablet blister pack.
These products are listed as being affected by “an unexpected increase in demand”.
Medsurge Health is also the distributor of the Teva-Prazosin products.
Necon 0.5/35 norethisterone 0.5mg and ethinylestradiol 35 microgram tablets (3 blister cards of 28 tablets) (manufactured by Teva Pharmaceuticals USA) have been approved as a replacement product for the following:
- Norimin 28 day tablet blister pack
- Brevinor 28 Day tablet blister pack
These products are listed as being unavailable due to manufacturing issues.
Clopidogrel 75mg tablets, manufactured by USP (USA) have been approved till 31 January 2021 as a replacement for:
- Plavix clopidogrel (as hydrogen sulfate) 75 mg tablet blister pack
- Clopidogrel GH clopidogrel (as besilate) 75mg film-coated tablet
These products are currently listed as being at limited availability due to discontinuation.
To see the full listings of new approvals, go here